vs

Side-by-side financial comparison of Hanover Bancorp, Inc. (HNVR) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $18.6M, roughly 1.9× Hanover Bancorp, Inc.). Hanover Bancorp, Inc. runs the higher net margin — 0.2% vs -304.2%, a 304.4% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 3.3%). Hanover Bancorp, Inc. produced more free cash flow last quarter ($12.2M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 6.1%).

Hanover Bancorp, Inc. is a U.S. regional bank holding company based in Maryland. It offers retail and commercial banking services including deposits, business loans, mortgages, personal lending and wealth management, serving consumers, SMEs and local groups across Maryland and adjacent mid-Atlantic markets.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

HNVR vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.9× larger
RXRX
$35.5M
$18.6M
HNVR
Growing faster (revenue YoY)
RXRX
RXRX
+678.4% gap
RXRX
681.7%
3.3%
HNVR
Higher net margin
HNVR
HNVR
304.4% more per $
HNVR
0.2%
-304.2%
RXRX
More free cash flow
HNVR
HNVR
$59.5M more FCF
HNVR
$12.2M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
6.1%
HNVR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HNVR
HNVR
RXRX
RXRX
Revenue
$18.6M
$35.5M
Net Profit
$33.0K
$-108.1M
Gross Margin
59.8%
Operating Margin
0.7%
-304.8%
Net Margin
0.2%
-304.2%
Revenue YoY
3.3%
681.7%
Net Profit YoY
-99.2%
39.6%
EPS (diluted)
$0.00
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HNVR
HNVR
RXRX
RXRX
Q4 25
$18.6M
$35.5M
Q3 25
$18.0M
$5.2M
Q2 25
$18.4M
$19.2M
Q1 25
$18.4M
$14.7M
Q4 24
$18.0M
$4.5M
Q3 24
$17.1M
$26.1M
Q2 24
$16.9M
$14.4M
Q1 24
$16.5M
$13.8M
Net Profit
HNVR
HNVR
RXRX
RXRX
Q4 25
$33.0K
$-108.1M
Q3 25
$3.5M
$-162.3M
Q2 25
$2.4M
$-171.9M
Q1 25
$1.5M
$-202.5M
Q4 24
$3.9M
$-178.9M
Q3 24
$3.5M
$-95.8M
Q2 24
$844.0K
$-97.5M
Q1 24
$4.1M
$-91.4M
Gross Margin
HNVR
HNVR
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
HNVR
HNVR
RXRX
RXRX
Q4 25
0.7%
-304.8%
Q3 25
25.9%
-3327.6%
Q2 25
18.4%
-916.8%
Q1 25
9.6%
-1297.9%
Q4 24
28.9%
-4042.4%
Q3 24
27.1%
-377.1%
Q2 24
6.9%
-697.4%
Q1 24
32.7%
-698.4%
Net Margin
HNVR
HNVR
RXRX
RXRX
Q4 25
0.2%
-304.2%
Q3 25
19.4%
-3135.3%
Q2 25
13.3%
-894.2%
Q1 25
8.3%
-1373.3%
Q4 24
21.7%
-3935.5%
Q3 24
20.7%
-367.5%
Q2 24
5.0%
-676.6%
Q1 24
24.6%
-662.4%
EPS (diluted)
HNVR
HNVR
RXRX
RXRX
Q4 25
$0.00
$-0.17
Q3 25
$0.47
$-0.36
Q2 25
$0.33
$-0.41
Q1 25
$0.20
$-0.50
Q4 24
$0.52
$-0.56
Q3 24
$0.48
$-0.34
Q2 24
$0.11
$-0.40
Q1 24
$0.55
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HNVR
HNVR
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$208.9M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$200.3M
$1.1B
Total Assets
$2.4B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HNVR
HNVR
RXRX
RXRX
Q4 25
$208.9M
$743.3M
Q3 25
$167.6M
$659.8M
Q2 25
$164.5M
$525.1M
Q1 25
$160.2M
$500.5M
Q4 24
$162.9M
$594.4M
Q3 24
$141.2M
$427.6M
Q2 24
$141.1M
$474.3M
Q1 24
$136.5M
$296.3M
Total Debt
HNVR
HNVR
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
HNVR
HNVR
RXRX
RXRX
Q4 25
$200.3M
$1.1B
Q3 25
$201.8M
$1.0B
Q2 25
$198.9M
$919.1M
Q1 25
$196.6M
$933.9M
Q4 24
$196.6M
$1.0B
Q3 24
$192.3M
$524.6M
Q2 24
$190.1M
$584.4M
Q1 24
$189.5M
$401.2M
Total Assets
HNVR
HNVR
RXRX
RXRX
Q4 25
$2.4B
$1.5B
Q3 25
$2.3B
$1.4B
Q2 25
$2.3B
$1.3B
Q1 25
$2.3B
$1.3B
Q4 24
$2.3B
$1.4B
Q3 24
$2.3B
$726.5M
Q2 24
$2.3B
$775.9M
Q1 24
$2.3B
$557.8M
Debt / Equity
HNVR
HNVR
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HNVR
HNVR
RXRX
RXRX
Operating Cash FlowLast quarter
$13.1M
$-46.1M
Free Cash FlowOCF − Capex
$12.2M
$-47.3M
FCF MarginFCF / Revenue
65.5%
-133.1%
Capex IntensityCapex / Revenue
4.7%
3.5%
Cash ConversionOCF / Net Profit
395.48×
TTM Free Cash FlowTrailing 4 quarters
$16.3M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HNVR
HNVR
RXRX
RXRX
Q4 25
$13.1M
$-46.1M
Q3 25
$2.7M
$-117.4M
Q2 25
$-2.1M
$-76.4M
Q1 25
$4.1M
$-132.0M
Q4 24
$5.4M
$-115.4M
Q3 24
$-547.0K
$-59.2M
Q2 24
$-3.1M
$-82.2M
Q1 24
$3.6M
$-102.3M
Free Cash Flow
HNVR
HNVR
RXRX
RXRX
Q4 25
$12.2M
$-47.3M
Q3 25
$2.4M
$-117.6M
Q2 25
$-2.2M
$-79.6M
Q1 25
$3.9M
$-133.8M
Q4 24
$4.1M
$-116.7M
Q3 24
$-876.0K
$-63.8M
Q2 24
$-4.5M
$-83.4M
Q1 24
$3.3M
$-109.0M
FCF Margin
HNVR
HNVR
RXRX
RXRX
Q4 25
65.5%
-133.1%
Q3 25
13.5%
-2272.5%
Q2 25
-11.7%
-413.9%
Q1 25
21.2%
-907.4%
Q4 24
23.1%
-2567.7%
Q3 24
-5.1%
-244.6%
Q2 24
-26.9%
-578.5%
Q1 24
19.9%
-789.9%
Capex Intensity
HNVR
HNVR
RXRX
RXRX
Q4 25
4.7%
3.5%
Q3 25
1.8%
4.7%
Q2 25
0.5%
16.4%
Q1 25
1.2%
12.4%
Q4 24
7.2%
28.6%
Q3 24
1.9%
17.5%
Q2 24
8.6%
8.2%
Q1 24
1.9%
48.2%
Cash Conversion
HNVR
HNVR
RXRX
RXRX
Q4 25
395.48×
Q3 25
0.79×
Q2 25
-0.84×
Q1 25
2.70×
Q4 24
1.39×
Q3 24
-0.15×
Q2 24
-3.68×
Q1 24
0.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons